Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.226
+0.005 (2.46%)
At close: Mar 6, 2026
Northwest Biotherapeutics Employees
Northwest Biotherapeutics had 25 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
25
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$37,480
Profits / Employee
-$3,648,960
Market Cap
360.56M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
| ZIVO Bioscience | 7 |
| Harvard Apparatus Regenerative Technology | 8 |
Northwest Biotherapeutics News
- 3 months ago - Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility - PRNewsWire
- 4 months ago - Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed - PRNewsWire
- 6 months ago - Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. - PRNewsWire
- 7 months ago - Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman - PRNewsWire
- 9 months ago - Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire